Literature DB >> 9874272

Molecular lysis of synovial lining cells by in vivo herpes simplex virus-thymidine kinase gene transfer.

S M Sant1, T M Suarez, M R Moalli, B Y Wu, M Blaivas, T J Laing, B J Roessler.   

Abstract

Herpes simples virus thymidine kinase (HSV-TK) expression plasmid DNA was injected into the joint space of rabbits with antigen-induced arthritis (AIA). Purified plasmid DNA was able to mediate transfection of synovial lining cells and transient overexpression of HSV-TK in the context of active synovial inflammation. The pharmacodynamic distribution of intraarticular expression plasmid DNA was confined to the joint space. Arthritic rabbits treated with intraarticular expression plasmid DNA followed by intravenous ganciclovir (GCV, 5 mg/kg) twice daily for 3 days showed histologic evidence of synovial lining layer cytolysis when articular tissues were examined 21 days posttreatment. There was also a reduction in joint swelling in the TK-treated knees. No untoward clinical effects were observed in the rabbits and no evidence of cytolytic damage specific to the TK-GCV gene therapy was observed either in the articular cartilage or bone. The application of TK-GCV intraarticular gene therapy using purified expression plasmid DNA for the induction of synovial cytolysis may be applicable to the treatment of human inflammatory arthritis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9874272     DOI: 10.1089/hum.1998.9.18-2735

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  9 in total

Review 1.  Gene therapy for autoimmune disorders.

Authors:  C H Evans; S C Ghivizzani; T J Oligino; P D Robbins
Journal:  J Clin Immunol       Date:  2000-09       Impact factor: 8.317

Review 2.  Getting arthritis gene therapy into the clinic.

Authors:  Christopher H Evans; Steven C Ghivizzani; Paul D Robbins
Journal:  Nat Rev Rheumatol       Date:  2010-12-07       Impact factor: 20.543

Review 3.  Perspectives on the use of gene therapy for chronic joint diseases.

Authors:  Steven C Ghivizzani; Elvire Gouze; Jean-Noel Gouze; Jesse D Kay; Marsha L Bush; Rachael S Watson; Padraic P Levings; David M Nickerson; Patrick T Colahan; Paul D Robbins; Christopher H Evans
Journal:  Curr Gene Ther       Date:  2008-08       Impact factor: 4.391

Review 4.  Gene therapy for rheumatoid arthritis.

Authors:  E Gouze; S C Ghivizzani; P D Robbins; C H Evans
Journal:  Curr Rheumatol Rep       Date:  2001-02       Impact factor: 4.686

Review 5.  Macrophages in rheumatoid arthritis.

Authors:  R W Kinne; R Bräuer; B Stuhlmüller; E Palombo-Kinne; G R Burmester
Journal:  Arthritis Res       Date:  2000-04-12

6.  Future of adenoviruses in the gene therapy of arthritis.

Authors:  C H Evans; S C Ghivizzani; T A Oligino; P D Robbins
Journal:  Arthritis Res       Date:  2001-02-19

Review 7.  Gene Therapy for Cartilage Repair.

Authors:  Henning Madry; Patrick Orth; Magali Cucchiarini
Journal:  Cartilage       Date:  2011-07       Impact factor: 4.634

Review 8.  Gene therapy of the rheumatic diseases: 1998 to 2008.

Authors:  Christopher H Evans; Steven C Ghivizzani; Paul D Robbins
Journal:  Arthritis Res Ther       Date:  2009-01-30       Impact factor: 5.156

Review 9.  Gene therapy in animal models of rheumatoid arthritis: are we ready for the patients?

Authors:  Fons A J van de Loo; Ruben L Smeets; Wim B van den Berg
Journal:  Arthritis Res Ther       Date:  2004-07-29       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.